Seres Therapeutics マネジメント

マネジメント基準チェック /34

Seres Therapeuticsの CEO はEric Shaffで、 Jan2019年に任命され、の在任期間は 5.83年です。の年間総報酬は$ 3.16Mで、 21.7%給与と78.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.1%を直接所有しており、その価値は$ 131.37K 。経営陣と取締役会の平均在任期間はそれぞれ5.2年と8.2年です。

主要情報

Eric Shaff

最高経営責任者

US$3.2m

報酬総額

CEO給与比率	21.7%
CEO在任期間	5.8yrs
CEOの所有権	0.1%
経営陣の平均在職期間	5.2yrs
取締役会の平均在任期間	8.2yrs

経営陣の近況

Recent updates

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

Nov 15

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

CEO報酬分析

Seres Therapeutics の収益と比較して、Eric Shaff の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$68m
Jun 30 2024	n/a	n/a	-US$162m
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$3m	US$685k	-US$114m
Sep 30 2023	n/a	n/a	-US$224m
Jun 30 2023	n/a	n/a	-US$153m
Mar 31 2023	n/a	n/a	-US$265m
Dec 31 2022	US$4m	US$662k	-US$250m
Sep 30 2022	n/a	n/a	-US$231m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$10m	US$625k	-US$66m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$3m	US$590k	-US$89m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	US$2m	US$540k	-US$70m
Sep 30 2019	n/a	n/a	-US$73m
Jun 30 2019	n/a	n/a	-US$78m
Mar 31 2019	n/a	n/a	-US$95m
Dec 31 2018	US$1m	US$435k	-US$99m
Sep 30 2018	n/a	n/a	-US$107m
Jun 30 2018	n/a	n/a	-US$92m
Mar 31 2018	n/a	n/a	-US$92m
Dec 31 2017	US$2m	US$377k	-US$89m

報酬と市場: Ericの総報酬 ($USD 3.16M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Ericの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Eric Shaff (48 yo)

5.8yrs

在職期間

US$3,158,336

報酬

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Eric Shaff	President	5.8yrs	US$3.16m	0.10% $ 131.4k
Lisa von Moltke	Executive VP & Chief Medical Officer	4.7yrs	US$1.57m	0.019% $ 25.0k
Teresa Young	Executive VP and Chief Commercial & Strategy Officer	4.4yrs	US$1.82m	0.053% $ 69.7k
Marella Thorell	Executive VP & CFO	less than a year	データなし	データなし
David Ege	Executive VP & Chief Technology Officer	4.1yrs	US$5.32m	0.046% $ 59.8k
Matthew Henn	Executive VP & Chief Scientific Officer	5.8yrs	US$1.67m	0.046% $ 60.0k
Carlo Tanzi	Investor Relations Officer	9yrs	データなし	データなし
Thomas DesRosier	Chief Legal Officer	8.5yrs	US$1.44m	0.079% $ 104.2k
Caroline Holda	Assistant General Counsel	no data	データなし	データなし

5.2yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: MCRBの経営陣は経験豊富で経験豊富です（平均在職期間は5.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Eric Shaff	President	5.8yrs	US$3.16m	0.10% $ 131.4k
Willard Dere	Independent Director	7.3yrs	US$225.23k	0.019% $ 24.5k
Dennis Ausiello	Independent Director	9.6yrs	US$222.27k	0% $ 0
Kurt Graves	Independent Director	9yrs	US$219.23k	0% $ 0
Richard Kender	Independent Director	10.1yrs	US$232.69k	0.037% $ 48.9k
Mark Wilcox	Member of Scientific Advisory Board	9.8yrs	データなし	データなし
Andrew Goodman	Member of Scientific Advisory Board	no data	データなし	データなし
Curtis Huttenhower	Member of Scientific Advisory Board	no data	データなし	データなし
Paul Biondi	Independent Director	4.7yrs	US$211.73k	0.028% $ 36.7k
Stephen Berenson	Independent Chairman	5.3yrs	US$249.23k	0.0021% $ 2.8k
Robert Jenq	Member of Scientific Advisory Board	no data	データなし	データなし
Elhanan Borenstein	Member of Scientific Advisory Board	no data	データなし	データなし

8.2yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: MCRBの取締役会は経験豊富であると考えられます ( 8.2年の平均在任期間)。

Seres Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Recent updates

New minor risk - Market cap size

Little Excitement Around Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Revenues As Shares Take 30% Pounding

New major risk - Financial position

Seres Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Price target increased by 18% to US$3.89

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Consensus EPS estimates upgraded to US$0.85 loss

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

Price target decreased by 14% to US$6.20

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

マネジメント基準チェック /34